Sofie Johansson-Lock
Odense, Denmark
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Five-year inhaled, systemic, and total corticosteroid exposure reduction during anti‒interleukin-5 receptor alpha treatment for severe asthma.
Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: January 21, 2026
Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/Rα biologic therapy response for severe asthma.
Journal: The European respiratory journal
Published: May 03, 2025
The impact of biologic therapy on work capacity and workforce attachment in patients with severe asthma.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: February 25, 2025
Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.
Journal: The European respiratory journal
Published: July 30, 2024
Titration of anti-IL-5 biologics in severe asthma: an open-label randomised controlled trial (the OPTIMAL study).
Journal: The European respiratory journal
Published: February 27, 2024
Tobacco Exposure and Efficacy of Biologic Therapy in Patients With Severe Asthma: A Nationwide Study From the Danish Severe Asthma Register.
Journal: The journal of allergy and clinical immunology. In practice
Published: June 16, 2023
Complete response to anti-interleukin-5 biologics in a real-life setting: results from the nationwide Danish Severe Asthma Register.
Journal: ERJ open research
Published: May 16, 2022
Surfactant protein D, Club cell protein 16, Pulmonary and activation-regulated chemokine, C-reactive protein, and Fibrinogen biomarker variation in chronic obstructive lung disease.
Journal: Respiratory research
Published: August 24, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026